British alliance on ninja antibodies
Enlarge image

BusinessUK

British alliance on ninja antibodies

03.04.2012 - London companies PolyTherics and Spirogen collaborate for better antibody-drug-conjugates (ADCs) in the fight against cancer.

London – The buzz around antibody-drug-conjugates (ADCs), the weapons of choice in the fight against cancer, just became more blatant. After last week’s news that a novel ADC company had been founded in Switzerland PolyTherics Limited from London (UK) announced on 2 April that it would join in the treasure hunt for promising ADC candidates. Just like the Swiss ADC Therapeutics Sarl, London-seated PolyTherics relies on the cytotoxic agents provided by Spirogen Limited. The two companies want to combine PolyTherics’ linker technology TheraPEG™ with Spirogen’s potent cytotoxic pyrrolobenzodiazepines („PBDs“). The aim is to connect PBDs via the new linker to antibodys or antibody fragments in a site-specific manner. PolyTherics CEO John Burt is enthusiastic: „This is an exciting opportunity to combine our validated conjugation technology with Spirogen’s potentially best-in-class PBD warheads.“ Also Spirogen CEO Chris Martin is convinced the collaboration will bear fruit: „ADCs will represent a significant medical breakthrough in cancer therapy. PolyTherics’ TheraPEG™ conjugation technology will broaden the applications where our PBD warheads and linkers can create highly potent potentially market-leading ADC candidates.“ Spirogen’s PBDs are DNA minor groove binding agents, which bind and cross-link specific DNA-sites. They block cell division in the targeted (cancer) cells without distorting their DNA helix, thus avoiding the common phenomenon of emergent drug resistance.

http://www.european-biotechnology-news.com/news/news/2012-02/uk-alliance-on-ninja-antibodies.html

R&DUKIreland

12.02.2016 The promise of the microbiome as the basis of new treatments has caught the attention of many. Now, UK biotherapeutics maker 4D pharma plc has padded its microbiome pipeline with the acquisition of Irish Tucana Health.

CommercialisationEU

10.02.2016 In future, meds will come in packages sporting a unique barcode and an anti-tampering device. These measures are part of the EU’s new regulation to safeguard against falsified medicines.

Clinical ResearchFrancePortugalEU

05.02.2016 It is not yet clear why a man died during a first-in-man clinical trial in January. A preliminary report found several “major shortcomings” by responsible CRO Biotrial. However, all regulations were complied with.

M&ASwitzerland

04.02.2016 After having dodged multiple takeover attempts by Monsanto last year, agrobusiness giant Syngenta has now agreed to be acquired by chemical corporation ChemChina. The Swiss company also announced plans to go public within a few years.

FinancingEUUKBelgium

01.02.2016 Newly formed Medicxi Ventures, a life sciences-dedicated VC firm based in London, Geneva and Jersey, has closed a €210m investment fund to reinvest in European early-stage assets.

ResearchUKEU

01.02.2016 Altering human DNA with the efficient gene editing method CRISPR/Cas9, especially germline modifications, was long considered a taboo. Now, however, UK scientists have received official approval to tinker with embryo DNA.

M&ASwedenIceland

28.01.2016 Swedish infectious disease specialist Enzymatica has bagged Icelandic company Zymetech, who produces the patent-protected enzyme used in Enzymatica’s own common cold blocker ColdZyme.

R&DUK

27.01.2016 Three UK universities have teamed up with three pharma companies to create the Apollo Therapeutics Fund. With the tech transfer fund, the consortium aims to develop scientific research into medicines.

Clinical TrialsGermany

25.01.2016 Affimed means to put a promising drug combination to the test. With support from MSD, the German biopharma will carry out clinical trials for an immunotherapy combining treatments of both companies.

AMREU

21.01.2016 Stop squandering antibiotics and make research profitable again: at the World Economic Forum in Swiss Davos, 83 pharmaceutical companies have called for a unified approach towards the threat of antimicrobial resistance.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • PAION (D)1.77 EUR63.89%
  • 4SC (D)2.95 EUR11.32%
  • BIONOR PHARMA (N)0.86 NOK8.86%

FLOP

  • STENTYS (F)2.83 EUR-26.30%
  • BIOTIE THERAPEUTICS (FI)0.14 EUR-22.22%
  • KARO BIO (S)24.60 SEK-16.04%

TOP

  • VERONA PHARMA (UK)3.40 GBP25.9%
  • IXICO (UK)35.75 GBP21.2%
  • SERODUS (N)2.71 NOK15.8%

FLOP

  • BIONOR PHARMA (N)0.86 NOK-47.2%
  • STENTYS (F)2.83 EUR-44.3%
  • MOLMED (I)0.24 EUR-35.1%

TOP

  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)24.60 SEK3053.8%
  • 4SC (D)2.95 EUR243.0%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)8.65 SEK-86.0%
  • BIOTEST (D)13.79 EUR-85.3%
  • EVOCUTIS (UK)0.08 GBP-69.2%

No liability assumed, Date: 13.02.2016